Serotonin reuptake inhibitor antidepressants, including selective serotonin reuptake
inhibitors (SSRIs; ie, citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine, and …

The field of psychiatry is hampered by a lack of robust, reliable and valid biomarkers that can
aid in objectively diagnosing patients and providing individualized treatment …

Mental health researchers and clinicians have long sought answers to the question “What
works for whom?” The goal of precision medicine is to provide evidence-based answers to …

Objectives. This 2013 update of the practice guidelines for the biological treatment of
unipolar depressive disorders was developed by an international Task Force of the World …

Objective: Major depressive disorder has been linked with inflammatory processes, but it is
unclear whether individual differences in levels of inflammatory biomarkers could help …

Major depressive disorder is a heritable psychiatric syndrome that appears to be associated
with subtle cellular and molecular alterations in a complex neural network. The affected …

To improve the 'personalized-medicine'approach to the treatment of depression, we need to
identify biomarkers that, assessed before starting treatment, predict future response to …

A revision of the 2008 British Association for Psychopharmacology evidence-based
guidelines for treating depressive disorders with antidepressants was undertaken in order to …

Abstract Remission rates for Major Depressive Disorder (MDD) are low and unpredictable
for any given antidepressant. No biological or clinical marker has demonstrated sufficient …

Major depressive disorder (MDD) is a common psychiatric illness with high levels of
morbidity and mortality. Despite intensive research during the past several decades, the …